AstraZeneca and Amgen collaborate on treatments for inflammatory diseases
AstraZeneca (NYSE:AZN) and Amgen (NYSE:AMGN) will collaborate on five monoclonal antibodies to treat inflammatory diseases in a move that could help AstraZeneca steer away from the patent cliff and put recent setbacks behind. The pharmaceutical companies will jointly develop and commercialize five Amgen drugs. AstraZeneca will pay an initial $50 million up front and shoulder […]